Classes
Publications
- Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters2015 | First Faculty of Medicine
- Rituximab in hands of a nephrologist - first experience2009 | First Faculty of Medicine
- Intracellular Cytokine Production in ANCA-associated Vasculitis: Low Levels of Interleukin-10 in Remission Are Associated with a Higher Relapse Rate in the Long-term Follow-up2009 | First Faculty of Medicine
- T cells in the pathogenesis of ANCA-associated vasculitis: current knowledge2008 | First Faculty of Medicine
- Retrospective assessment of routine ANCA detection: long-term single-centre experiencePublication without faculty affiliation
- Long-term follow-up of lymphocyte subpopulations and intracellular cytokines in patients with ANCA-associated vasculitis treated with rituximabPublication without faculty affiliation
- Complement System Deficiencies in Elite Athletes2024 | First Faculty of Medicine
- Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab2023 | First Faculty of Medicine
- SARS-CoV-2 Specific Humoral Immune Responses after BNT162b2 Vaccination in Hospital Healthcare Workers2022 | First Faculty of Medicine
- Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis2021 | First Faculty of Medicine
Loading network view...